Arrowhead Pharmaceuticals, Inc. (LON: 0HI3)
London
· Delayed Price · Currency is GBP · Price in USD 19.71
+0.01 (0.05%)
Jan 22, 2025, 6:52 PM BST
Arrowhead Pharmaceuticals Employees
Arrowhead Pharmaceuticals had 609 employees as of September 29, 2024. The number of employees increased by 84 or 16.00% compared to the previous year.
Employees
609
Change (1Y)
84
Growth (1Y)
16.00%
Revenue / Employee
4.35K GBP
Profits / Employee
-734.45K GBP
Market Cap
1.99B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 89,900 |
| GSK plc | 70,212 |
| Haleon | 25,408 |
| Smith & Nephew | 18,452 |
| ConvaTec Group | 10,136 |
| Hikma Pharmaceuticals | 9,100 |
| HUTCHMED (China) | 1,988 |
| Oxford Nanopore Technologies | 1,238 |
Arrowhead Pharmaceuticals News
- 5 days ago - Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome - Business Wire
- 23 days ago - Insider Sell: Adeoye Olukotun Sells Shares of Arrowhead Pharmaceuticals Inc - GuruFocus
- 4 weeks ago - Arrowhead Pharmaceuticals Initiates Clinical Trial for Obesity Treatment - GuruFocus
- 4 weeks ago - Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity - Business Wire
- 4 weeks ago - Arrowhead Pharmaceuticals Announces Inducement Grants for New Employees - GuruFocus
- 4 weeks ago - Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases - Business Wire
- 7 weeks ago - Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity - Business Wire